Crypto investor Will Harbone has launched LongGame, a $40 million venture capital fund dedicated to advancing longevity biotechnology, according to a Dec. 12 statement shared with CryptoSlate.
The initiative seeks to revolutionize human health by extending healthy lifespans over three decades through investments in innovative fields like stem cell research, gene editing, and senolytics.
LongGame targets early-stage biotech startups with scalable technologies, emphasizing pre-seed and seed investments. Beyond funding, the initiative aims to bridge biotechnology and decentralized science (DeSci), fostering collaboration between traditional life sciences and emerging decentralized technologies.
The fund plans to integrate tools like DAOs to streamline drug discovery and encourage patient-driven research. Over the next four years, LongGame intends to strategically allocate its capital while supporting global scalability for its portfolio companies.
The leadership team at LongGame includes COO Chloe Northcott, formerly of Geometry, and Special Advisor Sebastian A. Brunemeier, General Partner at Healthspan Capital. Dr. Manish Chamoli, the fund’s chief scientific officer, brings deep expertise in aging biology and longevity research from his tenure at the Buck Institute. This team will collaborate with specialists across various fields in medical science and biotechnology to advance its mission.
With his team, Harbone envisions leveraging blockchain innovations such as tokenization, crowdfunding, and liquidity solutions to address funding gaps in longevity research. These mechanisms aim to democratize access to life-extending therapies, ensuring they benefit a broad population rather than remaining exclusive to the wealthy.
He explained:
“Our goal is to fund therapies that do more than just extend life; we’re looking for solutions that radically expand the healthy human lifespan—by 30 years or more. We’re tackling the root causes of aging, not just the symptoms, and we want to ensure that these life-extending therapies are accessible to the masses, not just the wealthy.”
Harborne believes longevity innovation can potentially disrupt global industries, much like crypto reshaped traditional finance.
Meanwhile, this fund move aligns with a broader trend of crypto leaders entering the longevity space. Last year, Coinbase CEO Brian Armstrong co-founded NewLimit, a biotech firm that raised $40 million to advance age-related therapies.
Mentioned in this article
